These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21575037)

  • 1. Population diversity and the performance of warfarin dosing algorithms.
    Suarez-Kurtz G
    Br J Clin Pharmacol; 2011 Sep; 72(3):451-3. PubMed ID: 21575037
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
    Botton MR; Bandinelli E; Rohde LE; Amon LC; Hutz MH
    Br J Clin Pharmacol; 2011 Sep; 72(3):442-50. PubMed ID: 21320153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription.
    Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
    Ethn Dis; 2009; 19(4):479-80. PubMed ID: 20077595
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
    Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
    Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenetics: does more accurate dosing benefit patients?
    Eby C
    Semin Thromb Hemost; 2012 Oct; 38(7):661-6. PubMed ID: 23047421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
    Zhang X; Li L; Ding X; Kaminsky LS
    Drug Metab Dispos; 2011 Aug; 39(8):1433-9. PubMed ID: 21562147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inherited warfarin resistance in Indian patients: does it occur?
    Sharma V; Biswas A; Saxena R
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):455-6. PubMed ID: 17911202
    [No Abstract]   [Full Text] [Related]  

  • 10. The pharmacogenetics of the response to warfarin in Chinese.
    Lam MP; Cheung BM
    Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 17. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.
    Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH
    J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of warfarin pharmacogenetics in under-represented minority groups.
    Cavallari LH; Perera MA
    Future Cardiol; 2012 Jul; 8(4):563-76. PubMed ID: 22871196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic factors for warfarin dose prediction.
    Lippi G; Salvagno GL; Guidi GC
    Clin Chem; 2007 Sep; 53(9):1721-2. PubMed ID: 17712016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.